Overview
Top Medical Research Studies
Caregivers then reported on their infants’ health at 1, 3, and 6 months, sharing details about common illness symptoms. We found that DHA supplementation appeared to reduce the number of colds at one month and also seemed to lessen the duration of various cold symptoms in infants. Specifically, infants in the DHA group experienced fewer cold symptoms and had shorter durations of cough and wheezing.
While the overall occurrence of specific illness symptoms was similar between the DHA and placebo groups, DHA did bring about noteworthy benefits. At 1 month, infants in the DHA group had a 26% shorter duration of cough and 30% shorter wheezing; however, they experienced a longer duration of rash.
Furthermore, by the time the infants reached 3 months, those whose mothers took DHA were ill for 14% less time overall. At 6 months, the DHA group showed significantly reduced durations of several illness indicators, although they did experience longer episodes of vomiting.
This study suggests that prenatal DHA not only seems to impact the occurrence of colds in children but may also play a role in the duration of symptoms over the first half-year of life.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
Most Useful Reviews
Medical Researches
- All Researches
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
Caregivers then reported on their infants’ health at 1, 3, and 6 months, sharing details about common illness symptoms. We found that DHA supplementation appeared to reduce the number of colds at one month and also seemed to lessen the duration of various cold symptoms in infants. Specifically, infants in the DHA group experienced fewer cold symptoms and had shorter durations of cough and wheezing.
While the overall occurrence of specific illness symptoms was similar between the DHA and placebo groups, DHA did bring about noteworthy benefits. At 1 month, infants in the DHA group had a 26% shorter duration of cough and 30% shorter wheezing; however, they experienced a longer duration of rash.
Furthermore, by the time the infants reached 3 months, those whose mothers took DHA were ill for 14% less time overall. At 6 months, the DHA group showed significantly reduced durations of several illness indicators, although they did experience longer episodes of vomiting.
This study suggests that prenatal DHA not only seems to impact the occurrence of colds in children but may also play a role in the duration of symptoms over the first half-year of life.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
The common cold is a viral infection of the upper respiratory tract, primarily affecting the nose and throat. It's caused by a variety of viruses, with rhinoviruses being the most prevalent. Symptoms generally include a runny or stuffy nose, sore throat, cough, sneezing, mild headache, and sometimes a low-grade fever. While the common cold is often mild and resolves on its own within a week or two, it can still be bothersome and impact daily activities.
Transmission occurs through respiratory droplets when an infected person coughs or sneezes, or by touching surfaces contaminated with the virus. Preventative measures include frequent handwashing, using hand sanitizer, and avoiding close contact with infected individuals. Since there is currently no cure for the common cold, treatment focuses on symptom relief through over-the-counter medications, adequate rest, and hydration. While colds may be uncomfortable, they are generally not serious; however, seeking medical attention may be necessary if symptoms worsen or persist for an extended period.
Omega-3 fish oil is a nutritional supplement derived from the fatty tissues of fish, particularly fatty fish like salmon, mackerel, and sardines. It is rich in omega-3 fatty acids, which are essential fats that the body cannot produce on its own. The most significant types of omega-3s found in fish oil are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which are known for their numerous health benefits. These include reducing inflammation, supporting heart health, and promoting brain function.
Incorporating omega-3 fish oil into your diet can be beneficial if you don’t consume enough fish regularly. Many health experts recommend oily fish as a part of a balanced diet due to their high omega-3 content. For those who find it difficult to include fish in their meals, fish oil supplements can offer a convenient alternative, providing the same essential fatty acids in concentrated form. However, it’s essential to choose high-quality supplements that are third-party tested for purity and potency to avoid contaminants such as heavy metals or other toxins that can impact health.
Based on user reviews, the timeline for noticing results from taking Omega-3 supplements for cold-related symptoms can vary. Many users report significant benefits in their overall health and immunity after consistent use, with some claiming to experience a noticeable improvement in energy levels and a reduction in cold occurrences after several months of supplementation. For example, one user mentioned improvement in health with fewer ailments and no colds during the winter season after starting Omega-3 in September 2018 (Read Review).
Additionally, another reviewer emphasized that consistent use for over 10 years led to significant health improvements, including a dramatic reduction in cold symptoms (Read Review). Overall, users suggest that while some may feel the benefits sooner, committing to daily intake for a few months appears to be the key to achieving optimal results.
The scientific research surrounding supplements for the common cold presents a mixed bag of results. One notable study evaluated the effects of omega-3 fatty acids, specifically icosapent ethyl, on adults with cardiovascular disease at risk for viral upper respiratory infections. With a sizeable cohort of approximately 16,500 participants, the study failed to demonstrate significant benefits of this omega-3 supplement on the severity or impact of upper respiratory infections [1]. This suggests that while omega-3s might be beneficial for some health aspects, their efficacy in combatting the common cold remains unproven.
On a more positive note, research involving infants has shown potential benefits of specific omega-3 supplementation. One study investigated docosahexaenoic acid (DHA) in infant formula, revealing that infants consuming DHA had significantly lower rates of upper respiratory infections and allergic diseases compared to those on nonsupplemented formulas. Additionally, a separate study explored prenatal DHA supplementation, indicating that mothers taking DHA during pregnancy may have infants with fewer colds and shorter symptoms [2] [3]. Overall, while there is evidence supporting the role of DHA in reducing cold occurrences and symptoms in infants, other omega-3 supplements may not have the same effect, particularly in adults.
Based on user reviews, many individuals have reported notable improvements in their overall health and immune function after incorporating Omega-3 supplements into their daily routines. For instance, one user highlighted their return to revitalized health and better cholesterol regulation after resuming Omega-3 supplementation, which they had temporarily paused (Read Review). Another reviewer emphasized not having had any colds during the winter season since starting their supplementation in September 2018, further underscoring the potential immunity benefits (Read Review).
In addition, long-term users have reported remarkable reductions in cold symptoms, such as one reviewer who noted they had not experienced colds or swollen tonsils for over a decade due to consistent use of fish oil (Read Review). Others have experienced benefits in energy levels, with one reviewer linking their increased vitality during the pandemic to daily Omega-3 intake (Read Review). While individual results may vary, these anecdotal experiences highlight the diverse potential advantages of Omega-3 supplementation.
Users have reported positive experiences when combining Omega-3 supplements with other dietary supplements for managing the common cold. One long-term user noted that along with vitamin C and other supplements, their consistent intake of fish oil led to significant improvements in their health, including immunity and notable reductions in cold symptoms, such as swollen tonsils, which they used to experience every season (Read Review). This suggests that a multi-supplement approach may enhance the immune benefits provided by Omega-3.
Additionally, another reviewer mentioned using Omega-3 specifically for immune support, indicating that their family found it effective against colds. This user reported significant improvements after switching to a higher-rated Omega-3 product (Read Review). Overall, anecdotal evidence from user reviews suggests that integrating Omega-3 with other supplements like vitamin C might yield better protection against colds.
Based on user reviews, there seems to be a positive consensus on the benefits of Omega-3 Fish Oil in supporting immune health and potentially reducing the incidence of colds. Several users reported that they did not experience any colds during the winter months after incorporating Omega-3 into their routine. For instance, one user mentioned not having any colds this winter, even during the peak season, attributing their improved health and increased energy to the supplement (Read Review). Another user claimed to have avoided colds for over 10 years while consistently taking fish oil, indicating a strong link between the supplement and immune support (Read Review).
Regarding the optimal dose, the reviews don’t specify exact dosage recommendations, but one user expressed preference for a specific formulation containing EPA and DHA, suggesting that users may find a combination of these components beneficial (Read Review). Other users highlight the importance of consistent daily intake, noting that adherence to supplementation has resulted in marked health improvements, including immune resilience against colds (Read Review). Overall, while a specific dosage is not mentioned, the general sentiment supports regular intake for best results in maintaining immune health.
With about 16,500 participants, this clinical trial compared IPE treatment against usual care. The goal was to see if IPE could lessen the severity and impact of viral infections over six months.
Unfortunately, there was no significant evidence found that IPE improved outcomes for upper respiratory infections in this group.
In a well-structured, randomized, double-blind study, we followed children who received either supplemented or nonsupplemented formulas during their first year of life. Our findings showed that those on the DHA/ARA formula had significantly lower chances of developing upper respiratory infections and common allergic diseases.
Notably, the DHA/ARA group experienced a delayed onset and reduced incidence of respiratory issues, indicating potential benefits of early nutrition on long-term health.
Caregivers then reported on their infants’ health at 1, 3, and 6 months, sharing details about common illness symptoms. We found that DHA supplementation appeared to reduce the number of colds at one month and also seemed to lessen the duration of various cold symptoms in infants. Specifically, infants in the DHA group experienced fewer cold symptoms and had shorter durations of cough and wheezing.
While the overall occurrence of specific illness symptoms was similar between the DHA and placebo groups, DHA did bring about noteworthy benefits. At 1 month, infants in the DHA group had a 26% shorter duration of cough and 30% shorter wheezing; however, they experienced a longer duration of rash.
Furthermore, by the time the infants reached 3 months, those whose mothers took DHA were ill for 14% less time overall. At 6 months, the DHA group showed significantly reduced durations of several illness indicators, although they did experience longer episodes of vomiting.
This study suggests that prenatal DHA not only seems to impact the occurrence of colds in children but may also play a role in the duration of symptoms over the first half-year of life.
References
- Ambrosy AP, Malik UI, Thomas RC, Parikh RV, Tan TC, et al. Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021;235:54. doi:10.1016/j.ahj.2021.01.018
- Birch EE, Khoury JC, Berseth CL, Castañeda YS, Couch JM, et al. The impact of early nutrition on incidence of allergic manifestations and common respiratory illnesses in children. J Pediatr. 2010;156:902. doi:10.1016/j.jpeds.2010.01.002
- Imhoff-Kunsch B, Stein AD, Martorell R, Parra-Cabrera S, Romieu I, et al. Prenatal docosahexaenoic acid supplementation and infant morbidity: randomized controlled trial. Pediatrics. 2011;128:e505. doi:10.1542/peds.2010-1386
